Biotech News

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

ANI Pharmaceuticals (ANIP)ANI PharmaceuticalsEarnings

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET.

Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.

To view the webcast, please click here . Links to access the webcast and conference call will also be available on the “Events & Presentations” page of the Company’s website at https://www.anipharmaceuticals.com , under the “Investors” section. A replay of the event will remain accessible for up to one year.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations: Irina Koffler, Vice President, Investor Relations T: 917-734-7387 E: Irina.koffler@anipharmaceuticals.com

Media Relations: Argot Partners T: 212-600-1494 E: [email protected]

SOURCE: ANI Pharmaceuticals, Inc.

Related news

ANI Pharmaceuticals

Rare-Disease and Specialty Pharmaceuticals ANI Pharmaceuticals develops and commercializes medicines across rare disease, ophthalmology and established pharmaceutical markets. Its model combines branded specialty products with a portfolio of generic medicines. Cortrophin Gel Purified Cortrophin Gel is an adrenocorticotropic hormone...

Recent company news

Stock data

Close
82.63 USD
Market cap
1.7B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States